Differential Expression of MiR-139, MiR-486 and MiR-21 in Breast Cancer Patients Sub-classified According to Lymph Node Status

Overview

Journal Cell Oncol (Dordr)

Publisher Springer

Date 2014 Jul 17

PMID 25027758

Citations 40

Authors

Lene Rask

Eva Balslev

Rolf Sokilde

Estrid Hogdall

Henrik Flyger

Jens Eriksen

Thomas Litman

Affiliations

Soon will be listed here.

Abstract

Purpose: Therapeutic decisions in breast cancer are increasingly guided by prognostic and predictive biomarkers. Non-protein-coding microRNAs (miRNAs) have recently been found to be deregulated in breast cancers and, in addition, to be correlated with several clinico-pathological features. One of the most consistently up-regulated miRNAs is miR-21. Here, we specifically searched for differentially expressed miRNAs in high-risk breast cancer patients as compared to low-risk breast cancer patients. In the same patients, we also compared miR-21 expression with the expression of its presumed target PTEN.

Methods: Both microarray and RT-qPCR techniques were used to assess miRNA expression levels in lymph node-positive and -negative human invasive ductal carcinoma tissues. Simultaneously, PTEN protein expression levels were assessed using immunohistochemistry.

Results: miR-486-5p and miR-139-5p were found to be down-regulated in patients with lymph node metastases, whereas miR-21 was found to be up-regulated in patients with a positive lymph node status. miR-21 expression levels were found to significantly correlate with tumour size (r = 0.403, p = 0.009; Spearman's rank), whereas no relation was found between miR-21 and PTEN expression levels (Kruskal-Wallis test).

Conclusion: Down-regulation of miR-486-5p and miR-139-5p, in conjunction with up-regulation of miR-21, may represent a useful signature for the identification of high-risk breast cancer patients.

Citing Articles

The association between toenail metals and extracellular MicroRNAs (ex-miRNAs) among the participants of the Normative Aging study (NAS).

Danesh Yazdi M, Sonntag A, Kosheleva A, Nassan F, Wang C, Xu Z Environ Res. 2024; 261:119761.

PMID: 39122161 PMC: 11578093. DOI: 10.1016/j.envres.2024.119761.

Myogenic microRNAs as Therapeutic Targets for Skeletal Muscle Mass Wasting in Breast Cancer Models.

Artigas-Arias M, Curi R, Marzuca-Nassr G Int J Mol Sci. 2024; 25(12).

PMID: 38928418 PMC: 11204047. DOI: 10.3390/ijms25126714.

Dynamic miRNA profile of host T cells during early hepatic stages of infection.

Giri B, Li S, Fang C, Qiu L, Yan S, Pakharukova M Front Immunol. 2022; 13:911139.

PMID: 36119054 PMC: 9478579. DOI: 10.3389/fimmu.2022.911139.

Skeletal muscle-specific overexpression of miR-486 limits mammary tumor-induced skeletal muscle functional limitations.

Wang R, Kumar B, Doud E, Mosley A, Alexander M, Kunkel L Mol Ther Nucleic Acids. 2022; 28:231-248.

PMID: 35402076 PMC: 8971682. DOI: 10.1016/j.omtn.2022.03.009.

hsa_circ_0000218/hsa-miR-139-3p/SOX4 regulatory feedback circuit influences the proliferation and apoptosis of gastric cancer cells.

Xia G, Wang A, Li L Cytotechnology. 2022; 74(1):89-98.

PMID: 35185288 PMC: 8816988. DOI: 10.1007/s10616-021-00509-9.

References

Li W, Zhao B, Jin Y, Ruan K . Development of a low-cost detection method for miRNA microarray. Acta Biochim Biophys Sin (Shanghai). 2010; 42(4):296-301. DOI: 10.1093/abbs/gmq017. View

Bao W, Fu H, Xie Q, Wang L, Zhang R, Guo Z . HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology. 2011; 141(6):2076-2087.e6. DOI: 10.1053/j.gastro.2011.08.050. View

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo Y . MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008; 18(3):350-9. DOI: 10.1038/cr.2008.24. View

Mees S, Mardin W, Sielker S, Willscher E, Senninger N, Schleicher C . Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol. 2009; 16(8):2339-50. DOI: 10.1245/s10434-009-0531-4. View

Rask L, Fregil M, Hogdall E, Mitchelmore C, Eriksen J . Development of a metastatic fluorescent Lewis Lung carcinoma mouse model: identification of mRNAs and microRNAs involved in tumor invasion. Gene. 2013; 517(1):72-81. DOI: 10.1016/j.gene.2012.12.083. View

Yu L, Todd N, Xing L, Xie Y, Zhang H, Liu Z . Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer. 2011; 127(12):2870-8. PMC: 3545471. DOI: 10.1002/ijc.25289. View

Koshida S, Kobayashi D, Moriai R, Tsuji N, Watanabe N . Specific overexpression of OLFM4(GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis. Cancer Sci. 2007; 98(3):315-20. PMC: 11159027. DOI: 10.1111/j.1349-7006.2006.00383.x. View

Sempere L, Preis M, Yezefski T, Ouyang H, Suriawinata A, Silahtaroglu A . Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res. 2010; 16(16):4246-55. PMC: 3229296. DOI: 10.1158/1078-0432.CCR-10-1152. View

10.

Stuelten C, Salomon D . miR-31 in cancer: location matters. Cell Cycle. 2011; 9(23):4608-9. DOI: 10.4161/cc.9.23.13928. View

11.

Baffa R, Fassan M, Volinia S, OHara B, Liu C, Palazzo J . MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 2009; 219(2):214-21. DOI: 10.1002/path.2586. View

12.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

13.

Aigner A . MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs. J Mol Med (Berl). 2011; 89(5):445-57. DOI: 10.1007/s00109-010-0716-0. View

14.

Oh H, Tan A, Das K, Ooi C, Deng N, Tan I . Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res. 2011; 17(9):2657-67. DOI: 10.1158/1078-0432.CCR-10-3152. View

15.

Qi L, Bart J, Tan L, Platteel I, van der Sluis T, Huitema S . Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009; 9:163. PMC: 2695476. DOI: 10.1186/1471-2407-9-163. View

16.

Skalsky R, Cullen B . Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS One. 2011; 6(9):e24248. PMC: 3166303. DOI: 10.1371/journal.pone.0024248. View

17.

Alexander M, Casar J, Motohashi N, Myers J, Eisenberg I, Gonzalez R . Regulation of DMD pathology by an ankyrin-encoded miRNA. Skelet Muscle. 2011; 1:27. PMC: 3188430. DOI: 10.1186/2044-5040-1-27. View

18.

Mascaux C, Laes J, Anthoine G, HALLER A, Ninane V, Burny A . Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Respir J. 2008; 33(2):352-9. DOI: 10.1183/09031936.00084108. View

19.

Huang G, Zhang X, Guo G, Huang K, Yang K, Shen X . Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep. 2009; 21(3):673-9. View

20.

Madhyastha R, Madhyastha H, Nakajima Y, Omura S, Maruyama M . MicroRNA signature in diabetic wound healing: promotive role of miR-21 in fibroblast migration. Int Wound J. 2011; 9(4):355-61. PMC: 7950390. DOI: 10.1111/j.1742-481X.2011.00890.x. View